Theriva Biologics (TOVX) announced that the company had become aware of unusual trading activity in its common stock on the NYSE American on October 24. “The company has made inquiries and does not believe corrective actions are appropriate. The company is further announcing that there has been no material development in its business and affairs not previously disclosed or, to its knowledge, any other reason to account for the unusual market action. However, on October 13, 2025, the company announced the presentation of expanded data from its VIRAGE trial investigating VCN-01 at a mini oral session at the European Society for Medical Oncology Annual Congress,” the company stated.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TOVX:
- Theriva Biologics Presents Promising Phase 2b Trial Data
- Theriva Biologics Secures $4M Through Warrant Agreement
- Theriva Biologics announces warrant inducement transaction for $4M in proceeds
- Theriva Biologics Presents Promising VCN-12 Preclinical Data
- Theriva Biologics Unveils VCN-12 Preclinical Data